Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The aim was to test the protocol for obtaining lymphoid tissue from mouse lymph nodes and characterize the level of DNA damage with analysis of the repair and apoptosis protein markers in ex vivo model of cell irradiation. The lymph node cell suspension was exposed to X-ray irradiation at a dose of 2 Gy and compared with a sham-irradiated (0 Gy) control. Ex vivo irradiation at a dose of 2 Gy after 3 h caused a 7-fold increase in DNA damage level determined in DNA comet assay. A significant increase in the level of repair proteins γH2AX (by 3.7 times), Rad51 (by 2.2 times), and XPA (by 28 times), cell cycle arrest proteins Cdc25A (by 2.6 times), p21 (by 10 times), and p16 (by 5 times), and pro-apoptotic protein Bax (by 3.8 times) was noted, without significant changes in Bcl-2 level. The proposed technique allows quick obtaining lymphoid tissue samples suitable for analysis of the radiosensitivity of lymphoid cells in mice of various strains, changes in their sensitivity after or in combination with the primary damaging exposure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10517-025-06465-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Activatable and Covalent Tumor-Associated Antigen Capturer Enabling Systemic Injection for Promoted Antitumor Immunity.
J Am Chem Soc
September 2025
Frontiers Science Center for New Organic Matter, State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences and Academy for Advanced Interdisciplinary Studies, Nankai University, Tianjin 300071, PR China.
Antigen-capturing nanomaterials hold great promise for cancer immunotherapy; however, the need for tumor localized administration and limited antigen-binding affinity remains the "Achilles heel" of this strategy. Herein, we present a tumor microenvironment (TME)-activatable nanoplatform, TDR848@FPB, designed for systemic administration and enhanced covalent capture of tumor-associated antigens (TAAs), enabling effective immunotherapy with minimal off-target effects and independent of localized tumor administration. This platform encapsulates a photosensitizer-conjugated, light-activated toll-like receptor (TLR) agonist, which induces immunogenic cell death and triggers a pro-inflammatory TME conducive to antigen capture upon light irradiation.
View Article and Find Full Text PDFAn aptamer-conjugated mesoporous polydopamine formulation for synergistic targeted and photothermal therapy of hepatocellular carcinoma.
Int J Pharm X
June 2025
Medical School, Southeast University, Nanjing 210009, China.
This study aimed to create multifunctional nanoparticles (NPs), specifically AS1411@MPDA-Len-Cy5.5 (AMLC), for the purpose of developing effective strategies for treating hepatocellular carcinoma (HCC) through targeted therapy and photothermal therapy (PTT). The study involved synthesizing mesoporous polydopamine (MPDA)-NPs, loading lenvatinib (Len) and Cy5.
View Article and Find Full Text PDFPhotoacoustic-imaging nanomotors enhance tumor penetration and alleviate hypoxia for photodynamic therapy of breast cancer.
Biomater Sci
September 2025
Key Laboratory for Organic Electronics and Information Displays and Jiangsu Key Laboratory for Biosensors, Institute of Advanced Materials, Jiangsu National Synergetic Innovation Centre for Advanced Materials, Nanjing University of Posts and Telecommunications, Nanjing 210023, P.R. China. iamzgteng@
Breast cancer is the most prevalent malignancy worldwide, yet conventional therapies are invasive and prone to resistance, recurrence, and metastasis. Photodynamic therapy (PDT) is a promising noninvasive modality, but its efficacy is limited by tumor hypoxia and poor photosensitizer delivery. Here, we report a photoacoustic-imaging nanomotor, PPIC, which addresses these challenges through integrated functions of oxygen production, deep tissue penetration and photoacoustic imaging.
View Article and Find Full Text PDFFerroptosis-Enhanced Radiopharmaceutical Therapy via a Manganese-Based Nanoplatform.
Mol Pharm
September 2025
Department of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.
Radiopharmaceutical therapy (RPT) is a therapeutic strategy that delivers radionuclides in a targeted manner to achieve precise radiation-induced killing of tumor cells. While RPT primarily induces tumor cell death through apoptosis, resistance to apoptosis has been identified as a key mechanism underlying the radioresistance. Therefore, integrating nonapoptotic cell death pathways with RPT offers a promising strategy to enhance its therapeutic efficacy.
View Article and Find Full Text PDFAptamers as target-specific recognition elements in drug delivery.
Adv Drug Deliv Rev
September 2025
Biochemistry, CUNY Graduate Center, The City University of New York, 365 Fifth Avenue, New York, NY 10016, United States; Molecular, Cellular, and Developmental Biology, CUNY Graduate Center, The City University of New York, 365 Fifth Avenue, New York, NY 10016, United States; Chemistry, CUNY Gradua
Targeted drug delivery significantly enhances therapeutic efficacy across various diseases, particularly in cancer treatments, where conventional approaches such as chemotherapy and radiotherapy often cause severe side effects. In this context, nucleic acid aptamers-short, single-stranded DNA or RNA oligonucleotides capable of binding specific targets with high affinity-have emerged as promising tools for precision drug delivery and therapy. Aptamers can be selected against whole, living cells using SELEX and chemically modified for diverse applications.
View Article and Find Full Text PDF